Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

MRD Clinical Portfolio

Pipeline

Early Development

AV/CV

CLIA/FDA

Commercialized

ALL

Early Development

AV/CV

CLIA/FDA

Commercialized

FDA cleared
Bone Marrow
CLIA Validated
Blood

CLL

Early Development

AV/CV

CLIA/FDA

Commercialized

FDA cleared
Bone Marrow
FDA cleared
Blood

MM

Early Development

AV/CV

CLIA/FDA

Commercialized

FDA cleared
Bone Marrow
CLIA Validated
Blood

NHL1

Early Development

AV/CV

CLIA/FDA

Commercialized

CLIA Validated
cfDNA (DLBCL)
CLIA Validated
Blood

1 Available to order as a CLIA-validated laboratory developed test (LDT) service. This use has not been cleared or approved by the FDA.


clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary